Central Nervous System Stimulants - Pharmacokinetics
Research News and Information

Sunday, November 22, 2009

OROS methylphenidate for the treatment of adults with attention-deficit/hyperactivity disorder.

30 Jul 2009 Attention-deficit/hyperactivity disorder (ADHD) is one of the most common behavioral disorders in childhood. It continues into adulthood in up to 65% of patients. Methylphenidate (MPH) is one of the most commonly used pharmacological treatments for ... Read more...

Adenosine receptor antagonists and behavioral activation in NF-kappaB p50 subunit knockout mice.

5 Jun 2009 AIMS: Our previous work revealed that mice lacking the p50 subunit of transcription factor nuclear factor kappa B (NF-kappaB) (p50 KO mice) and genetically intact F2 mice have similar locomotion under basal conditions, yet p50 KO mice show greater ... Read more...

Effects of application to two different skin sites on the pharmacokinetics of transdermal methylphenidate in pediatric patients with attention-deficit/hyperactivity disorder.

30 May 2009 OBJECTIVE: This study was conducted to quantify the rate and extent of methylphenidate (MPH) absorption from a transdermal system when applied to two different skin sites in pediatric subjects with attention-deficit/hyperactivity disorder (ADHD). ... Read more...

Latest indexed articles for 'Central Nervous System Stimulants - Pharmacokinetics'

These are the very latest articles for this heading:

• Age-related changes in motor subtle signs among girls and boys with ADHD. 11 Oct 2009
• OROS methylphenidate for the treatment of adults with attention-deficit/hyperactivity disorder. 30 Jul 2009
• Armodafinil for the treatment of excessive sleepiness. 30 Jul 2009
• Adenosine receptor antagonists and behavioral activation in NF-kappaB p50 subunit knockout mice. 5 Jun 2009
• Effects of application to two different skin sites on the pharmacokinetics of transdermal methylphenidate in pediatric patients with attention-deficit/hyperactivity disorder. 30 May 2009
• Prenatal lead exposure enhances methamphetamine sensitization in rats. 7 May 2009
• [Drugs for attention deficit hyperactivity disorder] 29 Apr 2009
• Effects of major tanshinones isolated from Danshen (Salvia miltiorrhiza) on rat CYP1A2 expression and metabolism of model CYP1A2 probe substrates. 26 Apr 2009
• Juvenile methylphenidate exposure and factors that influence incentive processing. 15 Apr 2009
• Transfer of methylamphetamine and amphetamine into breast milk following recreational use of methylamphetamine. 30 Mar 2009
• Elimination of ephedrines in urine following administration of a Sho-seiryu-to preparation. 30 Mar 2009
• Armodafinil promotes wakefulness and activates Fos in rat brain. 24 Feb 2009
• Detox agents do not affect the pharmacokinetics of methamphetamine in the rat. 6 Feb 2009
• Novel biomarkers of prenatal methamphetamine exposure in human meconium. 30 Jan 2009
• Population pharmacokinetics of caffeine in healthy male adults using mixed-effects models. 30 Jan 2009
• Influences of urinary pH on the pharmacokinetics of three amphetamine-type stimulants using a new high-performance liquid chromatographic method. 30 Jan 2009
• Armodafinil and modafinil have substantially different pharmacokinetic profiles despite having the same terminal half-lives: analysis of data from three randomized, single-dose, pharmacokinetic studies. 30 Dec 2008
• Rapid simultaneous determination of paracetamol, amantadine hydrochloride, caffeine and chlorpheniramine maleate in human plasma by liquid chromatography/tandem mass spectrometry. 30 Dec 2008
• The efficacy and safety profile of lisdexamfetamine dimesylate, a prodrug of d-amphetamine, for the treatment of attention-deficit/hyperactivity disorder in children and adults. 30 Dec 2008
• Pharmacokinetic profile of armodafinil in healthy subjects: pooled analysis of data from three randomized studies. 30 Dec 2008

See a longer list of these articles.

Technical information about 'Central Nervous System Stimulants'

Definition: A loosely defined group of drugs that tend to increase behavioral alertness, agitation, or excitation. They work by a variety of mechanisms, but usually not by direct excitation of neurons. The many drugs that have such actions as side effects to their main therapeutic use are not included here.

Registry Number: 0

Descriptor UI: D000697

Alternative terms: Central Nervous System Stimulants; Central Stimulants; Stimulants, Central; Analeptics; Analeptic Drugs; Drugs, Analeptic; Analeptic Agents; Agents, Analeptic;

Allowable Qualifiers: administration & dosage; adverse effects; analysis; antagonists & inhibitors; blood; cerebrospinal fluid; chemical synthesis; classification; diagnostic use; economics; history; immunology; isolation & purification; metabolism; pharmacokinetics; pharmacology; poisoning; radiation effects; standards; supply & distribution; therapeutic use; toxicity; urine; chemistry; contraindications; agonists;

Tree Number: D27.505.696.282; D27.505.954.427.220;

Online Note: use CENTRAL NERVOUS SYSTEM STIMULANTS to search ANALEPTICS 1966-94

History Note: 95; was ANALEPTICS 1963-94; CENTRAL NERVOUS SYSTEM STIMULANTS was see ANALEPTICS 1985-94

Technical Notes: GEN or unspecified; prefer specifics; consider also CENTRAL NERVOUS SYSTEM /drug eff & BRAIN /drug eff; DF: CNS STIMULANTS